Anika Therapeutics Inc. (ANIK) announced after the bell Tuesday that its Phase 3 study of CINGAL 16-02 in patients with knee osteoarthritis failed to reach statistical significance in terms of the primary endpoint.
from RTT - Before the Bell https://ift.tt/2te6gtq
via IFTTT
No comments:
Post a Comment